arrow
A

Andrea Franson

University of Michigan Medical School
H指数:16
被引数:1,140

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N)

selpercatinib在RET突变肿瘤的儿童及青少年患者中的II期研究:NCI-COG Pediatric MATCH试验(APEC1621N)的N组

2026-10-130
OAAI
Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma

左乙拉西坦通过治疗性靶向弥漫性中线胶质瘤中的GABA能突触

2026-09-170
OAAI
Multi-Institutional Annotated Multiparametric MRI Dataset of Pediatric High-Grade Gliomas

多机构注释的儿科高级别胶质瘤多参数MRI数据集

2026-05-010
PRE
ZFTA-RELA ependymomas make itaconate to epigenetically drive fusion expression
Nature
IF48.5
2026-02-012
PRE
Leveraging the immunomodulatory effects of dordaviprone (ONC201) to induce long-term survival response in diffuse midline glioma patients and models

利用dordaviprone(ONC201)的免疫调节作用,在弥漫性中线胶质瘤患者和模型中诱导长期生存反应

2025-11-010
OAAI
Patient-derived tumor-oids recapitulate the tumor microenvironment and allow for pre-clinical drug screening across the entire spectrum of pediatric brain tumors

患者来源的类器官能够重现肿瘤微环境,并允许对整个谱系的儿童脑肿瘤进行临床前药物筛选。

2025-11-010
OAAI
LEVETIRACETAM THERAPEUTICALLY TARGETS GABAERGIC SYNAPSES IN DIFFUSE MIDLINE GLIOMA

左乙拉西坦通过治疗作用靶向弥漫性中线胶质瘤中的GABA能突触

2025-11-010
OAAI
Precision Targeting of PI3K/mTOR in Diffuse Midline Glioma: GCT007 as a Novel Brain-Penetrant PIK3CA Inhibitor

弥漫性中线胶质瘤中PI3K/mTOR的精确靶向:GCT007作为新型脑穿透性PIK3CA抑制剂

2025-11-010
OAAI
Tail ligation recombinase polymerase amplification sequencing (TLDRseq) enables sensitive, same-day, multi-gene sequencing for plasma-based detection and timely monitoring of brain tumor ctDNA

尾端连接重组酶聚合酶扩增测序(TLDRseq)能够实现对外周血浆中脑肿瘤细胞游离DNA(ctDNA)进行敏感、当天完成的多基因测序检测和及时监测。

2025-11-010
PRE
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis

异柠檬酸脱氢酶1为组3型髓母细胞瘤的铜死亡做准备

2025-05-150
PRE
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

在FIREFLY-1试验中,托瓦雷芬尼(tovorafenib)这种II型RAF抑制剂对复发性/难治性视神经通路胶质瘤患儿的放射学和视觉反应。

2024-12-190
PRE
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL
2024-11-110
PRE
SOMATICTP53, PIK3R1, NF1 ORTERT MUTATIONS ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOME IN H3K27M-ALTERED DIFFUSE MIDLINE GLIOMA: AN INTERNATIONAL, MULTI-INSTITUTIONAL STUDY
2024-11-110
PRE
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
2024-11-110
PRE
PNOC008: A PILOT TRIAL TESTING THE CLINICAL BENEFIT OF USING MOLECULAR PROFILING TO DETERMINE AN INDIVIDUALIZED TREATMENT PLAN IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (EXCLUDING DIFFUSE INTRINSIC PONTINE GLIOMA)
2024-11-110
PRE